ArticleJournal of diabetes science and technology2011
Automated near-continuous glucose monitoring measured in plasma using mid-infrared spectroscopy.
Article in Journal of diabetes science and technology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Accuracy and stability of an arterial sensor for glucose monitoring in a porcine model using glucose clamp technique.Scientific reports · 2020Article
- Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care.SAGE open medicine · 2020Review
- Glucose Management Technologies for the Critically Ill.Journal of diabetes science and technology · 2019Review
- Manual versus Automated moNitoring Accuracy of GlucosE II (MANAGE II).Critical care (London, England) · 2016Article
- Vascular Glucose Sensor Symposium: Continuous Glucose Monitoring Systems (CGMS) for Hospitalized and Ambulatory Patients at Risk for Hyperglycemia, Hypoglycemia, and Glycemic Variability.Journal of diabetes science and technology · 2015Review
- Why Have So Many Intravascular Glucose Monitoring Devices Failed?Journal of diabetes science and technology · 2015Review
- Accuracy and limitations of continuous glucose monitoring using spectroscopy in critically ill patients.Annals of intensive care · 2014Article
- Interstitium versus Blood Equilibrium in Glucose Concentration and its Impact on Subcutaneous Continuous Glucose Monitoring Systems.European endocrinology · 2014Article
- In vitro glucose measurement using tunable mid-infrared laser spectroscopy combined with fiber-optic sensor.Biomedical optics express · 2013Article
- Accuracy of point-of-care glucose measurements.Journal of diabetes science and technology · 2012Review
- Glucose measurement of intensive care unit patient plasma samples using a fixed-wavelength mid-infrared spectroscopy system.Journal of diabetes science and technology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThere are increasing calls for a precise, automated system to enable tight glycemic control and to avoid hypoglycemia in an intensive care unit setting. OptiScan Biomedical has developed a glucose monitor based on mid-infrared spectroscopy that withdraws blood samples (120 µl) and measures plasma glucose. The goal of this study was to validate the performance of the OptiScan Model 5000 over a wide range of glycemic levels in patients. RESEARCH DESIGN AND
methodsSixty people with type 1 (n = 18) or type 2 (n = 42) diabetes who were otherwise healthy were connected to OptiScanners. Their blood glucose concentrations were kept in a euglycemic, hypoglycemic (<75 mg/dl), and hyperglycemic (>180 mg/dl) range by intravenous administrations of insulin and glucose. OptiScanner venous blood samples were automatically withdrawn every 15 minutes. Reference measurements were done using the YSI 2300 glucose analyzer.
resultsThe aggregate data points (1155 paired readings) were within International Organization for Standardization standards, with 98.6% of the glucose values within ±20% above 75 mg/dl and ±15 mg/dl below this value. A Clarke error grid analysis showed a total of 1139 points (98.6%) in zone A. Points outside of A exceeded the A zone boundary by an average of 4.3%. The r(2) was 0.99. The total coefficient for variance was 6.4%.
conclusionsThese results show that the OptiScanner is highly accurate in healthy patients with diabetes across a wide range of glucose values. Mid-infrared spectroscopy may become the method of choice for highly accurate, high frequency, automated glucose measurements and may thus enable better glycemic control in critically ill patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.